At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Jun 29, 2026 at 08:00 ET
Replimune reported a fiscal Q4 2026 EPS miss of -$0.77 vs -$0.72 consensus, a -6.9% surprise, with no revenue. The highlight is FDA acceptance of the RP1 BLA resubmission with a PDUFA date of August 2, 2026, and an advisory committee expected in late July, representing a pivotal near-term catalyst.
- FDA accepted RP1 BLA resubmission for advanced melanoma; PDUFA date August 2, 2026
- Advisory committee meeting expected in late July 2026
- Fiscal Q4 2026 EPS -$0.77 vs consensus -$0.72 (miss of $0.05)
- Cash and equivalents $268.9M as of March 31, 2026; cash runway into Q1 2027
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access